LG Chem ((LGCLF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
LG Chem is conducting a clinical study titled A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Vaccine, in Healthy Infants as Primary Series. The study aims to assess the immunogenicity, safety, and consistency of the LBVD vaccine compared to existing vaccines in infants, highlighting its potential significance in pediatric immunization.
The intervention being tested is the LBVD vaccine, a fully liquid hexavalent vaccine designed to protect against six diseases, including diphtheria, tetanus, pertussis, hepatitis B, poliovirus, and Haemophilus influenzae type b.
This is an interventional study with a randomized, parallel assignment model. It is open-label, meaning no masking is used. The primary purpose of the study is prevention, focusing on evaluating the vaccine’s effectiveness and safety.
The study began on May 30, 2025, with the primary completion and estimated study completion dates still pending. The last update was submitted on June 30, 2025, indicating ongoing recruitment and progress.
The successful development of the LBVD vaccine could positively impact LG Chem’s stock performance by enhancing its portfolio in the competitive vaccine market. This update may influence investor sentiment, given the increasing demand for comprehensive immunization solutions.
The study is currently ongoing, with further details available on the ClinicalTrials portal.